Enrique A. Hernandez-Bustamante

Prof. Enrique A. Hernandez-Bustamante

Universidad Nacional de Trujillo, Trujillo, La Libertad, Peru
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
JUJuan R. Ulloque-Badaracco
Juan R. Ulloque-Badaracco
EAEsteban A. Alarcón-Braga
Esteban A. Alarcón-Braga
EHEnrique A. Hernandez-Bustamante
Enrique A. Hernandez-Bustamante
Ali Al-kassab-CórdovaAli Al-kassab-Córdova
Ali Al-kassab-Córdova
VBVicente Aleixandre Benites-Zapata
Vicente Aleixandre Benites-Zapata
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
Vaccination it is considered a vital strategy in order to mitigate monkeypox by protecting from severe disease and helping in reduction of hospitalisations. In this sense, this study aims to estimate the global prevalence of vaccination acceptance against monkeypox. We conducted a systematic review with a comprehensive search strategy for the following databases: PubMed, Scopus and Web of Science. A random-effect model meta-analysis was carried out using observational studies assessing the intention of vaccines against monkeypox from multiple continents. The quality assessment was developed using the Newcastle-Ottawa Scale adapted for cross-sectional studies. In addition, a subgroup analysis by study location and population and a sensitivity analysis was developed.Eleven cross-sectional studies were included. A total of 8045 participants were included. The pooled prevalence of monkeypox vaccination acceptance in all participants was 56.0% (95%CI: 42.0–70.0%). In the subgroup analysis of monkeypox vaccine acceptance according to continents, the prevalence of vaccine acceptance was 50.0% (95%CI: 24.0–76.0%) in Asian countries and 70.0% (95%CI: 55.0–84.0%) in European countries. The prevalence of vaccine acceptance was 43.0% (95%CI: 35.0–50.0%) in the general population, 63.0% (95%CI: 42.0–70.0%) in healthcare workers, and 84.0% (95%CI: 83.0–86.0%) in the LGBTI community. Despite the high prevalence of monkeypox vaccination acceptance in the LGBTI community found in our study, vaccination acceptance from healthcare workers and the general population are lower. Governments could use these results for planning, developing or promoting vaccination strategies and public health policies focused on these populations.

10 August 2022 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
JUJuan R. Ulloque-Badaracco
Juan R. Ulloque-Badaracco
MRMELANY MOSQUERA ROJAS
MELANY MOSQUERA ROJAS
EHEnrique A. Hernandez-Bustamante
Enrique A. Hernandez-Bustamante
EAEsteban A Alarcón-Braga
Esteban A Alarcón-Braga
RURicardo R. Ulloque-Badaracco
Ricardo R. Ulloque-Badaracco
AHAdrian V. Hernandez
Adrian V. Hernandez
Background and Aims. Biomarkers are necessary to stratify the risk of diabetic foot ulcers (DFUs). This systematic review and meta‐analysis aimed to evaluate the association between the lipid profile and apolipoproteins with the risk of DFU. Methods. A systematic search was conducted in PubMed, Scopus, Cochrane Library, and Web of Science among adult patients. Cohort and case‐control studies were included. Random‐effects models were used for meta‐analyses, and the effects were expressed as odds ratio (OR) and their 95% confidence intervals (CIs). We evaluated publication bias through Egger’s test and funnel plot. Results. A total of 12 cohort studies and 26 case‐control studies were included, with 17076 patients. We found that the higher values of total cholesterol (TC), low‐density lipoprotein (LDL), triglycerides, and lipoprotein(a) (Lp(a)) were associated with a higher risk of developing DFU (OR: 1.47, OR: 1.47, OR: 1.5, OR: 1.85, respectively). Otherwise, the lower values of HDL were associated with a higher risk of developing DFU (OR: 0.49). Publication bias was not found for associations between TC, HDL, LDL, or TG and the risk of DFU. Conclusions. The high values of LDL, TC, TG, and Lp(a) and low values of HDL are associated with a higher risk of developing DFU. Furthermore, we did not find a significant association for VLDL, ApoA1, ApoB, and ApoB/ApoA1 ratio.

6 November 2021 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
JUJuan R. Ulloque-Badaracco
Juan R. Ulloque-Badaracco
EHEnrique A. Hernandez-Bustamante
Enrique A. Hernandez-Bustamante
PHPercy Herrera-Añazco
Percy Herrera-Añazco
VBVicente Aleixandre Benites-Zapata
Vicente Aleixandre Benites-Zapata

1 May 2024 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
DBD. Katterine Bonilla-Aldana
D. Katterine Bonilla-Aldana
JBJorge Luis Bonilla-Aldana
Jorge Luis Bonilla-Aldana
JUJuan R. Ulloque-Badaracco
Juan R. Ulloque-Badaracco
Ali Al-kassab-CórdovaAli Al-kassab-Córdova
Ali Al-kassab-Córdova
EHEnrique A. Hernandez-Bustamante
Enrique A. Hernandez-Bustamante
JSJosé Antonio Suárez
José Antonio Suárez
: Snakebites still constitute a significant public health problem in developing countries and are considered a neglected tropical condition by the WHO. Snake accidents are associated with substantial morbidity and mortality and may produce secondary complications, such as severe infections. The objective of this systematic review was to determine the prevalence of snakebite infections and characterize the bacteria isolated from these infections. A systematic literature review in five databases was carried out to assess the prevalence of snakebite infection. A meta-analysis was performed using a random-effects model to calculate the pooled prevalence and 95% CIs. Cochran’s Q test and the I2 statistic were used to assess between-study heterogeneity. The pooled prevalence of infection due to snakebite was 27.0% (95% CI: 22.0–32.0%), with high heterogeneity among studies (I2 = 99.7%). The prevalence was higher in Asia (32%) than in the Americas (21%). Snakebite infections required surgical interventions in 68% (95% CI: 37.0–98.0%). The leading group of pathogens identified corresponded to Gram-negative bacteria (63%), particularly Morganella morganii (32%), but also, Gram-positive cocci (40%), especially Enterococcus spp. (23%) and Staphylococcus aureus (15%). However, multiple other pathogens, including anaerobes, were found. A high prevalence of snakebite-associated infection has been described, primarily due to M. morganii, with the corresponding implications for empirical therapy. Rational use of antimicrobials is recommended, and this should guide initial empirical treatment. Moreover, isolation and identification of the possible bacteria present in snakebite wounds is recommended in all cases to confirm or rule out associated infection.

Verified
Journal Article
Open access
PDF file
HZHernán J. Zavalaga-Zegarra
Hernán J. Zavalaga-Zegarra
JPJuan J. Palomino-Gutierrez
Juan J. Palomino-Gutierrez
JUJuan R. Ulloque-Badaracco
Juan R. Ulloque-Badaracco
MRMELANY MOSQUERA ROJAS
MELANY MOSQUERA ROJAS
EHEnrique A. Hernandez-Bustamante
Enrique A. Hernandez-Bustamante
Adrian V. HernandezAdrian V. Hernandez
Adrian V. Hernandez
C-reactive protein-to-albumin ratio (CAR) is an independent risk factor in cardiovascular, cerebrovascular, and infectious diseases. Through this study, we investigated the CAR values with respect to the severity and mortality of COVID-19 patients. We performed a systematic review and meta-analysis to retrieve studies that evaluated CAR values upon hospital admission in relation to the severity or mortality of COVID-19 patients. We adopted a random-effect model to calculate the pooled mean difference (MD) and their 95% confidence intervals (CI). Quality assessment was appraised using a Newcastle–Ottawa scale and publication bias was assessed using the Begg-test and funnel plot. We equally performed a subgroup analysis using study location and a sensitivity analysis only with studies with low risk of bias. We analyzed 32 studies (n = 12445). Severe COVID-19 patients had higher on-admission CAR values than non-severe COVID-19 patients (MD: 1.69; 95% CI: 1.35–2.03; p < 0.001; I2 = 89%). Non-survivor patients with COVID-19 had higher CAR values than survivor patients (MD: 2.59; 95% CI: 1.95–3.23; p < 0.001; I2 = 92%). In sensitivity analysis, the relationship remained with a decreasing of heterogeneity for severity (MD: 1.22; 95% CI: 1.03–1.40; p < 0.001; I2 = 13%) and for mortality (MD: 2.99; 95% CI: 2.47–3.51; p < 0.001; I2 = 0%). High CAR values were found in COVID-19 patients who developed severe disease or died.

22 February 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
FSFarley Salazar
Farley Salazar
VVValeria A. Valdez-Cornejo
Valeria A. Valdez-Cornejo
JUJuan R. Ulloque-Badaracco
Juan R. Ulloque-Badaracco
EHEnrique A. Hernandez-Bustamante
Enrique A. Hernandez-Bustamante
EAEsteban A. Alarcón-Braga
Esteban A. Alarcón-Braga
Adrian V. HernandezAdrian V. Hernandez
Adrian V. Hernandez
The systemic immune-inflammation index (SIII) is a marker studied in multiple types of urologic cancer. This systematic review evaluates the association between SIII values with overall survival (OS) and progression-free survival (PFS) in testicular cancer. We searched observational studies in five databases. The quantitative synthesis was performed using a random-effects model. The risk of bias was assessed using the Newcastle–Ottawa Scale (NOS). The only measure of the effect was the hazard ratio (HR). A sensitivity analysis was performed according to the risk of bias in the studies. There were 833 participants in a total of 6 cohorts. We found that high SIII values were associated with worse OS (HR = 3.28; 95% CI 1.3–8.9; p < 0.001; I2 = 78) and PFS (HR = 3.9; 95% CI 2.53–6.02; p < 0.001; I2 = 0). No indication of small study effects was found in the association between SIII values and OS (p = 0.5301). High SIII values were associated with worse OS and PFS. However, further primary studies are suggested to enhance the effect of this marker in different outcomes of testicular cancer patients.